Company Profile

Eutropics Pharmaceuticals Inc
Profile last edited on: 3/23/2018      CAGE: 4BBT8      UEI: VYD9LKBYHHQ3

Business Identifier: Advancing personalized medicine: guiding patient cancer treatment
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

767-C Concord Avenue
Cambridge, MA 02138
   (617) 714-4405
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Eutropics Pharmaceuticals, Inc. is working on development and discovery of clinical tools to aid in the diagnosis and treatment of cancer. Organized around an effort to displace current treatment paradigms by developing novel therapies tailored to an individual's cancer profile that would be identified by the firm's proprietary diagnostic technology, the approach is designed to illuminate the path to more effective treatments and reduce unnecessary suffering. The company's technology platform, PraediCare Dx, delivers in vitro diagnostic assays. As a start-up, the firm came out of Harvard Medical School, Dana Farber Cancer Institute and MIT and received support from the state’s Life Sciences Center

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Michael H Cardone -- Founder, President and CEO

  Ej Dettman -- Director of Clinical Diagnostics

Company News

There are no news available.